ICU Medical (NASDAQ:ICUI) Given New $153.00 Price Target at Piper Sandler

by · The Cerbat Gem

ICU Medical (NASDAQ:ICUI – Free Report) had its target price raised by Piper Sandler from $145.00 to $153.00 in a report published on Wednesday morning, Marketbeat.com reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently issued reports on ICUI. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. Raymond James Financial lowered their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $181.00.

View Our Latest Report on ICU Medical

ICU Medical Trading Down 3.4%

Shares of ICU Medical stock opened at $130.38 on Wednesday. ICU Medical has a 12-month low of $107.00 and a 12-month high of $196.26. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -85.78 and a beta of 0.86. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. The company’s 50-day moving average price is $126.23 and its 200-day moving average price is $133.86.

ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. During the same period in the prior year, the firm posted $1.56 earnings per share. The company’s revenue for the quarter was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, equities analysts expect that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director David C. Greenberg purchased 1,200 shares of the firm’s stock in a transaction on Wednesday, August 27th. The shares were purchased at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the purchase, the director owned 7,960 shares of the company’s stock, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction dated Thursday, August 14th. The stock was acquired at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. Deutsche Bank AG lifted its stake in ICU Medical by 41.1% in the fourth quarter. Deutsche Bank AG now owns 21,792 shares of the medical instruments supplier’s stock worth $3,381,000 after purchasing an additional 6,345 shares during the last quarter. Gotham Asset Management LLC grew its stake in shares of ICU Medical by 22.3% during the fourth quarter. Gotham Asset Management LLC now owns 40,610 shares of the medical instruments supplier’s stock valued at $6,301,000 after buying an additional 7,410 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ICU Medical by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,204 shares of the medical instruments supplier’s stock worth $1,894,000 after buying an additional 478 shares during the period. Occudo Quantitative Strategies LP purchased a new position in shares of ICU Medical in the fourth quarter worth about $911,000. Finally, Quantedge Capital Pte Ltd bought a new stake in shares of ICU Medical in the 4th quarter valued at about $2,529,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Further Reading